drugset / Trial / NCT07391241

A Phase 2 Study to Evaluate the Efficacy and Safety of Pudafensine in Vulvodynia (Provoked Vestibulodynia)

NCT07391241

Phase 2 Recruiting 24 enrolled Initiator Pharma
RandomizedCrossoverDouble-blindTreatment

Summary

The study (IP2015CS05) is a randomised, double-blind, placebo-controlled, 4-way cross-over trial studying the efficacy and safety of single dose administration of pudafensine in vulvodynia (provoked vestibulodynia) patients.

Timeline

Start
2025-12-17
Primary completion
2026-09-01
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pudafensine Small molecule

Indications